Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Smoldering Multiple Myeloma × isatuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 52 Neoplasms 6 Recurrence 5 Neoplasms, Plasma Cell 4 Renal Insufficiency 3 Paraproteinemias 3 Lymphoma 3 Hematologic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Hematologic Diseases 2 Blood Protein Disorders 2 Smoldering Multiple Myeloma 1 Purpura 1 Prostatic Neoplasms 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoproliferative Disorders 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Immunoproliferative Disorders 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Lenalidomide 16 Dexamethasone 13 Calcium Dobesilate 7 daratumumab 5 carfilzomib 4 Melphalan 4 dexamethasone acetate 3 dexamethasone 21-phosphate 3 auricularum 3 Curcumin 3 elotuzumab 2 Peripheral Blood Stem Cell Transplantation 2 PVX-410 vaccine 2 Leflunomide 2 Denosumab 2 Cyclophosphamide 2 Bortezomib 2 siltuximab 1 selinexor 1 sargramostim 1 pomalidomide 1 poly ICLC 1 piperine 1 pembrolizumab 1 ixazomib 1 isatuximab 1 ibrutinib 1 iberdomide 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡